| Symbol | HIGR |
|---|---|
| Name | HI-GREAT GROUP HOLDING CO. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 90005 United States CA 621 South Virgil Avenue #470 |
| Telephone | (213)-219-7746 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | US |
| Incorporated On | 2019 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | M.N. Vijay Kumar; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001807616 |
| Description | Hi-Great Group Company has been refocusing our efforts on an exclusive global licensing agreement pertaining to the KRAS gene. This gene is frequently mutated in a variety of cancers, including those affecting the pancreas, lungs, and colon, and is considered a pivotal "driver" mutation in cancer initiation. We will also uphold our commitment to marketing, selling, and distributing SellaCare, Inc.s organic longevity health supplement under our existing worldwide exclusive license agreement. Furthermore, we plan to diversify into the thriving cosmetic sector as a strategic component of our sustainable revenue approach, all while retaining our presence in the other six industry sectors. Additional info from OTC: |
No news found.